Rhenman & Partners Asset Management Ab Xenon Pharmaceuticals Inc. Transaction History
Rhenman & Partners Asset Management Ab
- $1.2 Billion
- Q3 2024
A detailed history of Rhenman & Partners Asset Management Ab transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 35,000 shares of XENE stock, worth $1.34 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
35,000
Previous 35,000
-0.0%
Holding current value
$1.34 Million
Previous $1.36 Million
0.95%
% of portfolio
0.11%
Previous 0.13%
Shares
1 transactions
Others Institutions Holding XENE
# of Institutions
212Shares Held
70.2MCall Options Held
88.3KPut Options Held
28.8K-
Avoro Capital Advisors LLC New York, NY5.67MShares$217 Million3.36% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.6MShares$176 Million1.77% of portfolio
-
Wellington Management Group LLP Boston, MA3.84MShares$147 Million0.03% of portfolio
-
Braidwell LP Stamford, CT2.71MShares$104 Million3.02% of portfolio
-
Commodore Capital LP New York, NY2.7MShares$103 Million9.03% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.39B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...